medication adherence

Medication Adherence: Why Cost Is the Barrier You Can Actually Fix

August 11, 2026

Key Takeaways

Cost is the #1 fixable barrier.
Prescription abandonment peaks at high costs.
Real-time pricing tools boost adherence by 20%.
Generic substitution saves up to 90%.
Non-adherence doubles hospitalization risk.

Managing expenses for medication and health supplies on a notebook

The Inside Rx Blog

Get the Inside Scoop on tips & tricks that may help your family save on prescriptions!

Subscribe to stay up to date with the latest news and tips

Medication adherence remains a critical challenge affecting up to 50% of patients with chronic conditions. The consequences are severe: over $300 billion in avoidable healthcare costs and 125,000 preventable deaths each year. Non-adherence leads to worse outcomes, uncontrolled chronic conditions and higher hospitalization rates. But one of the most common reasons for medication non adherence is also one of the most fixable: cost. About 47% of patients report spending less on simple needs to afford their medications. The importance of medication adherence becomes clear when you recognize that cost barriers, unlike behavioral or cognitive factors, allow for immediate and practical solutions.

What is medication adherence (and why it matters)

Defining medication adherence

The World Health Organization defines medication adherence as "the degree to which the person's behavior corresponds with the agreed recommendations from a health care provider". This definition marks a change from the older term "compliance," which implied passive patient obedience. Adherence recognizes that patients and physicians work together to improve health by integrating medical opinion with the patient's lifestyle, values and care priorities.

Adherence refers to whether patients take medications as prescribed (such as twice daily) and whether they continue taking a prescribed medication over time. You measure adherence as the percentage of prescribed doses taken over a specified period.

Understanding medication non-adherence

Medication non-adherence takes several distinct forms. Primary non-adherence occurs when providers write prescriptions but patients never fill or start them. About 28% of new prescriptions fall into this category in the United States. After acute myocardial infarction hospitalization, nearly 24% of patients don't even fill their cardiac medications by day seven of discharge.

Non-persistence happens when patients stop taking a medication after starting it without professional guidance. Studies show that about half of all patients prescribed antihypertensive medications stopped taking them within one year of the first prescription. Among patients discharged with prescriptions for aspirin, statin and β-blockers after acute myocardial infarction, about 34% stopped at least one medication and 12% stopped all three within one month.

Non-conforming behavior has skipping doses, taking medications at incorrect times or doses, or taking more than prescribed. Patients omit about 10% of scheduled medication doses on any given day.

Non-adherence can be unintentional or intentional. Unintentional non-adherence arises from capacity and resource limitations that prevent you from implementing treatment decisions. These barriers include problems accessing prescriptions, cost issues, competing demands, poor inhaler technique or forgetting doses. Intentional non-adherence stems from beliefs, attitudes and expectations that influence your motivation to begin and persist with treatment. Research shows that about half of non-adherence is intentional, while the remainder occurs because patients are unaware they're not taking medications as prescribed or the regimen is too complex.

The importance of medication adherence in chronic disease management

Adherence rates among patients with chronic illnesses average only 50% in developed countries. These patients take only about 50% of medications prescribed for chronic conditions. The gap between acute and chronic conditions is important: adherence rates are higher for acute conditions compared to chronic ones.

Poor adherence causes disease progression, reduced functional abilities, lower quality of life and increased use of medical resources including nursing homes and hospital visits. The risk of hospitalization more than doubles in patients with diabetes mellitus, hypercholesterolemia, hypertension or congestive heart failure who are non-adherent compared with adherent patients.

Non-adherence to cardioprotective medications was associated with a 10% to 40% relative increase in cardiovascular hospitalizations and a 50% to 80% relative increase in mortality risk in cardiovascular disease. Each incremental 25% increase in proportion of days covered for statin medications was associated with about a 3.8-mg/dL reduction in LDL cholesterol.

The financial impact is staggering. Direct healthcare costs associated with non-adherence have grown to about $100 to $300 billion spent each year in the United States. Higher adherence to prescribed medications for congestive heart failure, high blood pressure and high LDL cholesterol reduced annual healthcare spending per person by an estimated $7,800, $3,900 and $1,250 respectively, compared to patients with poorer adherence.

Cost is the most common reason patients skip medications

Research identifies cost as the main barrier to medication adherence. More than two-thirds of patients with diabetes or hypertension skip or delay medications, and cost remains the most common reason. Nearly one in four Americans taking prescription medications report difficulty affording them. This financial pressure translates into concrete decisions at the pharmacy counter and in daily life.

How prescription costs drive non-adherence

About 25% of adult patients prescribed medications face challenges with out-of-pocket costs. The burden has grown as cost-sharing structures evolved from simple one or two-tier systems to three or four tiers with wider differences, averaging $11 for tier 1, $35 for tier 2, $62 for tier 3, and $116 for tier 4. Annual deductibles in employee-sponsored health insurance plans increased by 59% for beneficiaries with single coverage from 2005 to 2016.

These increases outpaced wage growth. The average family in a large-employer plan paid more than $3,000 in out-of-pocket costs on top of $5,000 in premium costs by 2018. Out-of-pocket healthcare costs consumed 10% or more of annual income for many households. The relationship between cost-sharing and medication adherence appears strongest in cardiovascular disease compared to oncology or diabetes treatments.

Adults aged 18-64 who took prescription medication reported not taking medication as prescribed due to cost at a rate of 8.2% in 2021. Cost-saving measures included skipping doses, taking less medication than prescribed, and delaying prescription fills. Over 20% of those 65 and older experienced cost-related medication non-adherence in 2022.

Patients choosing between necessities and medications

The financial strain forces impossible choices. Forty-seven percent of respondents with low income reported spending less on at least one necessity to pay for medications, and 32% spent less on more than one. The tradeoffs patients make reveal the severity of the problem:

80.2% spent less on food
49.2% reduced transportation expenses
47.6% cut utilities spending
27.8% sacrificed housing costs
23.0% reduced other medical expenses

Those spending less on necessities to afford medications were more likely to have fair or poor health status, greater numbers of chronic conditions, and higher medication expenditure. Spending less on necessities was associated with decreased odds of medication adherence and a greater number of unmet needs over the past 12 months. Many respondents experienced worry about making monthly living expenses (80.8%), difficulty sleeping due to financial worries (64.5%), and strained interpersonal relationships from financial problems (61.8%).

The prescription abandonment problem at the pharmacy counter

Prescription abandonment occurs when a provider writes a prescription but the patient never picks it up at the pharmacy or obtains it. Approximately 9% of all prescriptions were abandoned at retail pharmacies in 2019. The abandonment rate climbs with cost: when cost sharing exceeded $500 per fill, abandonment reached about 60%.

The pattern is clear across price points. When commercial patients faced out-of-pocket costs exceeding $250, 69% did not start therapy. Only 11% of patients whose final out-of-pocket costs were less than $30 failed to start therapy. Abandonment ranges from 8% when drug costs fall between $0-$9.99 to 21% when costs reach $40-$49.99.

Uninsured adults face the highest barriers: 22.9% did not take medications as prescribed, compared to 8.0% with Medicaid and 6.5% with private health insurance. Most patients who abandon a prescription do not fill any prescription within three months, which suggests they are not switching to lower-cost alternatives but instead failing to start treatment as prescribed.

The real cost of cost-related medication non-adherence

When patients don't take medications as prescribed, the consequences ripple through the healthcare system. The toll reaches over $300 billion in avoidable healthcare costs and 125,000 preventable deaths each year. Non-adherence ranks as a top contributor to chronic condition progression, hospitalizations and readmissions.

Avoidable hospitalizations and emergency visits

Medication non-adherence drives up to 69% of medication-related hospitalizations. Patients who missed just one CMS Star Ratings adherence measure experienced 12% to 26% increased risks for all-cause and diabetes-related inpatient stays. The risks climb sharply as non-adherence worsens. Those missing two or three measures saw 22% to 42% increased risks, while missing four or more measures raised risks by 24% to 50%.

Emergency department visits follow the same pattern. Non-adherent patients faced 12% to 26% higher rates of all-cause and diabetes-related ED visits. Among diabetes patients, non-adherence to oral antidiabetic medications was linked to 27% higher all-cause and 21% higher diabetes-related hospital visits. Patients with the highest adherence experienced 36% reduced odds of ED visits and 44% reduced odds of hospitalization in internal medicine wards compared to those with the lowest adherence.

Effect on chronic disease progression

Beyond hospitalizations, non-adherence accelerates disease progression itself. Non-adherent diabetes patients showed higher glycosylated hemoglobin, elevated systolic and diastolic blood pressure, and increased LDL cholesterol levels. Multivariable analyzes showed that medication non-adherence remained linked to increased risks for all-cause hospitalization (odds ratio 1.58) and all-cause mortality (odds ratio 1.81). Each 25% increase in adherence to antihypertensive medication reduced systolic blood pressure by 1.0 mm Hg and diastolic by 1.2 mm Hg.

The $100+ billion burden on the healthcare system

Direct healthcare costs tied to non-adherence range from $100 billion to $300 billion each year in the United States. Research indicates the total costs of non-adherence to the U.S. healthcare system may reach as high as $528 billion per year. Patients who missed adherence quality measures experienced 14%, 19%, and 20% higher monthly medical costs when missing one, two or three, and four or more measures.

How poor adherence affects quality metrics and reimbursement

Beyond clinical and financial effects, non-adherence erodes performance metrics critical to value-based care. Poor adherence lowers CMS Star Ratings, HEDIS metrics and payer contracts. Health plans that performed well on Part D medication adherence measures (≥4-stars) had a higher likelihood of performing well on the Part C all-cause readmission measure. An analysis by CMS found that higher adherence in the 2020-2021 Medicare population was linked to reductions in total healthcare costs of $12.4 to $15.7 billion for RASA medications, $11.6 billion for statins, and $0.5 to $1.8 billion for diabetes medications.

Why cost barriers are actually solvable (unlike other adherence issues)

Cost vs. other adherence barriers

Cost is fundamentally different from other medication adherence barriers. Forgetfulness, cognitive decline, and complex medication regimens require sustained behavioral interventions with uncertain outcomes. Financial barriers respond to direct intervention. You know a medication costs $150 and the patient can afford $30. The solution becomes tangible: find a $30 alternative or assistance program.

Cost ranks as a prominent barrier to medication adherence among people with low income. The challenge becomes acute at the time patients must choose between medications and necessities like food, housing, or utilities. Physicians report thinking about patients' out-of-pocket costs in 58% of prescriptions. But prescribers face information gaps concerning list prices and copayments. This makes it difficult to respond unless changes are large and adopted across insurers.

Transparent pricing makes immediate effect

Prescription price transparency tools at the point of care address this information gap. Physicians access pricing information during patient encounters and can discuss therapeutic options. They review financial assistance if cost creates a barrier. The effect is measurable: combined with e-prescribing, access to group-level formulary information at the point of care increases first-fill medication adherence by 20%.

Technology-enabled affordability solutions

The October 1, 2025 HHS final rule makes it possible for health care providers using certified health IT systems to submit prior authorizations electronically, select drugs consistent with a patient's insurance coverage, and exchange electronic prescription information with pharmacies and insurance plans. These tools allow prescribers to compare drug prices in real time during care encounters and identify lower-cost alternatives available under a patient's insurance coverage.

Adoption accelerated faster than expected. The number of prescribers using Real-Time Prescription Benefit increased more than fortyfold since its 2017 launch and reached over 100,000 prescribers by December 2018. For prescriptions flagged for prior authorization, 28% changed to a drug with no prior authorization required. This saved 158,000 hours of potential wait time in December 2018 alone.

Practical solutions to fix cost-related non-adherence

Prescription discount programs and how they work

Prescription discount cards partner with pharmacies to negotiate reduced cash-pay rates on medications. These programs provide discounts when you pay out of pocket. The amount spent doesn't count toward your insurance deductible though. Programs like Inside Rx and state initiatives offer free cards that can reduce prescription costs up to 80%.

Connecting patients to affordable pricing at point of care

Real-Time Benefit Check technology embedded within electronic health records displays your individual-specific out-of-pocket price for specific medications during encounters. The price reflects your formulary, remaining deductible, and pharmacy choice. Healthcare providers report needing expanded support to compare medication costs. They need tools that show exact price differences across payment options.

Generic substitution and therapeutic alternatives

Replacing high-cost generics with lower-cost alternatives of the same clinical value produces savings of nearly 90%. High-cost generics were 15.6 times more expensive than their therapeutic alternatives. Most substitutions with different dosage forms or strengths of the same drug provided discounts of 94.9% and 77.1%.

Patient assistance programs and manufacturer coupons

Pharmaceutical manufacturers sponsor patient assistance programs that provide financial assistance or free medications if you have low income. Manufacturer copay cards offset out-of-pocket costs for brand-name medications, usually for patients with private insurance. Eligibility requirements vary. Some programs restrict use by Medicare or Medicaid beneficiaries.

How providers and pharmacies can intervene

Healthcare providers reduce medication non-adherence by switching to generic medications and connecting patients to discount programs. They also refer to assistance resources. Pharmacists review orders to prevent double copays and identify cost-saving opportunities. Interventions averaged $2,757 in cost avoidance per case.

The Inside Rx prescription discount card works like a coupon to save on the cost of prescription medication at your local pharmacy.

Zepbound

^$ 418.25

Pen Injector, 5mg/0.5ml (Package Of 2.0 Mls)

1 Package

Lexapro

^$ 518.38

Tablet, 5 Mg

30 Tablets

Conclusion

Medication non-adherence drives avoidable hospitalizations, worse outcomes and billions in downstream costs. Prescription price remains one of the biggest problems and one of the easiest to solve. Patients abandon prescriptions at the counter, and everyone in the care chain loses.

Cost barriers differ from behavioral or cognitive adherence challenges because they respond to direct intervention. You don't need to wait for behavioral change if you can connect patients to transparent, discounted pricing that keeps therapy within reach. Solutions like Inside Rx help providers and pharmacies address cost-related non-adherence with practical tools that make medications affordable at the point of care.

References

Topics:

Health Tips for Women Health Tips for Men Prescription Savings